LIXT
Lixte Biotechnology Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.21
−6.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 496.8K | 254.9K | 726.2K | 898.1K | 1.3M |
| SG&A Expense | 5.9M | 4.9M | 2.8M | 4.2M | 5.0M |
| General & Admin Expense | 5.9M | 4.9M | 2.8M | 4.2M | 5.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 6.4M | 5.1M | 3.6M | 5.1M | 6.3M |
| Cost and Expenses | 6.4M | 5.1M | 3.6M | 5.1M | 6.3M |
| Operating Income (EBIT) | (6.4M) | (5.1M) | (3.6M) | (5.1M) | (6.3M) |
| Non-Operating | |||||
| Interest Income | 10.3K | 7.4K | 7.0K | 17.5K | 11.2K |
| Interest Expense | 9.1K | 9.2K | 16.8K | 16.2K | 8.9K |
| Net Interest Income | 1.2K | (1.8K) | (9.8K) | 1.3K | 2.3K |
| Other Non-Op Income/Expense | (949.9K) | (901.9K) | (13.2K) | 3.2K | (1.1K) |
| Non-Operating Income (excl Interest) | 943.8K | 892.7K | (3.6K) | (19.4K) | (7.8K) |
| EBT (Pre-Tax Income) | (7.3M) | (6.0M) | (3.6M) | (5.1M) | (6.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.3M) | (6.0M) | (3.6M) | (5.1M) | (6.3M) |
| Earnings from Cont. Ops | (7.3M) | (6.0M) | (3.6M) | (5.1M) | (6.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.3M) | (6.1M) | (3.6M) | (5.1M) | (6.3M) |
| Per Share | |||||
| Basic EPS | ($1.13) | ($1.26) | ($1.59) | ($2.66) | ($4.00) |
| Diluted EPS | ($1.13) | ($1.26) | ($1.59) | ($2.66) | ($4.00) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 10.9M | 48.4M | 2.2M | 1.9M | 1.6M |
| Diluted Shares Outstanding | 10.9M | 48.4M | 2.2M | 1.9M | 1.6M |
| Profitability Metrics | |||||
| EBITDA | (7.3M) | (6.0M) | (3.6M) | (5.1M) | (6.3M) |
| D&A | — | — | — | — | — |
| EBIT | (7.3M) | (6.0M) | (3.6M) | (5.1M) | (6.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026